Arrowhead | Cafepharma

As Arrowhead falters, lungs remain a tough target for RNA drugs

Submitted by admin on Wed, 07/07/2021 - 11:00

snippet

Safety concerns in animal tests led Arrowhead Pharmaceuticals to suspend testing of a closely watched drug for cystic fibrosis, the latest setback for an RNA-based medicine against the genetic lung disease.

Source

BioPharma Dive

Headline

As Arrowhead falters, lungs remain a tough target for RNA drugs

News Tags

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Submitted by admin on Thu, 10/04/2018 - 10:22

snippet

Johnson & Johnson has paid $175 million upfront for the global rights to Arrowhead’s phase 1/2 RNAi hepatitis B drug. The outlay, plus $1.6 billion in milestones, has bought J&J a drug that slashed levels of hepatitis B virus in a small, early-phase assessment.

Source

Fierce Biotech

Headline

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepa…

News Tags

3 Biotech Stocks That Soared This Week

Submitted by admin on Sat, 05/12/2018 - 13:10

snippet

ARMO BioSciences (NASDAQ:ARMO), Opko Health (NASDAQ:OPK), and Arrowhead Pharmaceuticals (NASDAQ:ARWR) chalked up huge gains over the last five days. What sent these biotech stocks into orbit?